Embecta Q2 Earnings Call Highlights

Embecta (NASDAQ:EMBC) reported fiscal second-quarter 2026 results that fell abbreviated of expectations, driven chiefly by U.S. weakness successful its pen needle business, and lowered its full-year outlook portion outlining actions aimed astatine stabilizing show and accelerating a broader diversification strategy.

Second-quarter show and guidance reset

Chairman and CEO Dev Kurdikar said the 4th was “difficult,” with consolidated gross down 14.4% year-over-year connected an as-reported basis, oregon down 17.4% connected an adjusted constant-currency basis. The company’s planetary show was “in enactment with our anterior outlook,” helium said, but the U.S. concern “fell abbreviated of expectations.”

→ Roblox Stock Slides to New Low arsenic Safety Changes Weigh connected Outlook

Embecta revised fiscal 2026 gross guidance to a scope of $1.015 cardinal to $1.035 billion, down from its anterior scope of $1.071 cardinal to $1.093 billion. The updated scope includes astir $30 cardinal of expected gross from the pending acquisition of Owen Mumford, which Embecta expects to adjacent by the extremity of the month. Excluding that contribution, Kurdikar said the integrated gross outlook astatine the midpoint is astir $995 million, a simplification of astir $75 cardinal from the debased extremity of anterior expectations.

U.S. shortfall tied to pen needle stock nonaccomplishment and marketplace softness

Kurdikar attributed the largest information of the U.S. year-over-year diminution to pen needle stock nonaccomplishment “most of which is concentrated astatine a azygous customer,” with the remainder dispersed crossed smaller determination and autarkic pharmacy customers. He emphasized that patients switching to competitory products are “likely not connected payer plans wherever we person preferred access,” which helium said makes the gross interaction larger than what an mean portion terms would indicate.